> SAFETY · TOLERABILITY · ADVERSE EVENTS
Tirzepatide side effects: what the research shows.
GI adverse events, the gallbladder signal, the thyroid boxed warning, lean-mass loss, and hair shedding — all from the published trial and pharmacovigilance record.
> the short version
Tirzepatide side effects are well documented in large clinical trials and pharmacovigilance databases. The most common are gastrointestinal — nausea, vomiting, diarrhea, constipation — and they are dose-related, most frequent during dose escalation, and mostly mild to moderate.
Beyond GI events, two signals warrant specific attention: a significantly increased risk of gallbladder or biliary disease across multiple pooled analyses, and a boxed warning on the prescribing label about thyroid C-cell tumors observed in rodents (not confirmed in humans). Both are detailed below with their citations. For the full catalog of what people actually report — including anecdotal accounts not in the trial record — see the Tirzepatide effects page.
Gastrointestinal side effects: the dominant signal
Gastrointestinal adverse events are the most common tirzepatide side effects across every major trial. Nausea, vomiting, diarrhea, constipation, and decreased appetite are dose-dependent, emerging chiefly during the stepwise dose increase and generally easing with continued exposure.
A meta-analysis of 13 randomized controlled trials in 26,894 people with obesity without diabetes found overall GI adverse events were significantly higher for tirzepatide (RR 2.94, 95% CI 2.61-3.32 versus placebo) compared with a selective GLP-1 agonist (RR 1.68) [15]. These events drove the majority of discontinuations.
A pharmacovigilance (post-market safety reporting) analysis of the FDA Adverse Event Reporting System (FAERS) found a median time to GI event onset of approximately 16 days, with most events occurring within the first three months [17]. Incorrect dose administration was the single most frequently reported event in one FAERS series, underscoring the importance of the labeled titration schedule [16].
A 2026 bibliometric and pharmacovigilance analysis documented the GI adverse-event profile comprehensively [18]. A 2025 analysis also characterized GI tolerability alongside weight reduction [9].
For comparison: does tirzepatide cause diarrhea? Yes — diarrhea is among the phase 3 trial-documented adverse events, with rates higher than placebo at all maintenance doses and generally higher than a selective GLP-1 agonist comparator.
Gallbladder and biliary disease: a documented risk
Across multiple pooled analyses, tirzepatide is associated with a significantly increased risk of the composite of gallbladder or biliary disease.
The core meta-analysis of nine RCTs (9,871 participants) found RR 1.97 (95% CI 1.14-3.42) for the composite gallbladder-or-biliary-disease outcome versus controls [4]. A separate meta-analysis of 12 trials (25 studies for the biliary endpoint) reported RR 1.52 for gallbladder/biliary disease and RR 1.67 for cholelithiasis (gallstones) [21]. A class-level cardiovascular meta-analysis of 99,599 patients found gallbladder disorders increased approximately 26% [22].
Rapid weight loss is a well-established precipitant of gallstones, which fits the mechanism: as fat is mobilized rapidly, the liver secretes more cholesterol into bile, which can supersaturate and crystallize. The association with rapid weight loss rather than the drug itself has not been conclusively separated in the available data.
Thyroid C-cell tumors: boxed warning
The FDA prescribing label carries a boxed warning (the most prominent safety warning in the US labeling system) regarding the risk of thyroid C-cell (medullary) tumors. This warning is derived from rodent studies — in which the drug class caused dose- and duration-dependent thyroid C-cell tumors — and whether this signal translates to humans is not established [5].
Because of this unconfirmed signal, the label states tirzepatide should not be used by people with: [danger] A personal or family history of medullary thyroid carcinoma [danger] Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
A state-of-the-art safety review lists medullary thyroid carcinoma among rare, theoretical class associations rather than a demonstrated human risk [17]. This is a label-mandated contraindication grounded in animal data, not confirmed human outcomes. The clinical reference summary confirms this regulatory context [34].
If a person has either of the above histories, the drug is contraindicated.
Pancreatitis: monitored but not confirmed at trial level
Pancreatitis (inflammation of the pancreas) is a monitored class concern for incretin-based therapies. It is listed on the tirzepatide label.
The dedicated meta-analysis of nine RCTs found no statistically significant increase versus controls: RR 1.46 (95% CI 0.59-3.61) [4]. The wide confidence interval reflects limited power to detect a rare event. A FAERS disproportionality analysis captured approximately 190 pancreatitis reports [20]. Notably, a large propensity-matched retrospective cohort found a lower five-year pancreatitis recurrence rate among tirzepatide users who had a prior episode [19].
People should be alert to severe, persistent abdominal pain during treatment, as this can be a symptom of pancreatitis.
Hair loss and lean-mass loss: two additional signals
Two additional tirzepatide side effects are documented, both related to rapid weight reduction rather than direct drug toxicity.
Hair loss (telogen effluvium): Diffuse, temporary hair shedding triggered by the physiological stress of rapid weight reduction, not by a direct drug mechanism. Clinical trial data recorded hair loss in approximately 4-5% of tirzepatide participants versus 1% in placebo groups. A 2025 pharmacovigilance review of the GLP-1 receptor agonist class documented this signal [14]. It is typically self-limiting once weight stabilizes.
Lean-mass loss: A meaningful fraction of the weight lost during tirzepatide treatment is lean mass rather than fat. A SURMOUNT-1 DXA (bone density scan) substudy found approximately 25% of the weight lost was lean mass [6]. A 2026 systematic review across incretin trials put the median muscle-attributable share of weight loss near 28% [26]. A narrative review characterized the lean-mass loss as comparable to a decade or more of aging and recommended resistance exercise to help preserve muscle [27]. For the full analysis of what this means and what the studies recommend, see the tirzepatide muscle loss page.